Replies to post #102 on Dermata Therapeutics Inc (DRMA)

[The Night Stalker]

phase 2 topline results hence pop from .98 to 3.93. under 5m marketcap while its peers have large marketcaps, balance sheet looks good, this small offering dont scare me its not the end of world folks, will average down next week

[The Night Stalker]

Currently, Dermata has a Zacks Rank #3 (Hold).

Some better-ranked stocks for investors interested in the same sector are CRISPR Therapeutics CRSP, Kala Pharmaceuticals KALA and Allogene Therapeutics ALLO, each carrying a Zacks Rank #2 (Buy)